DISCLAIMER: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
June 10, 2025
Company name: Pharma Foods Inc.
Listing: Tokyo Stock Exchange
Securities code: 2929
URL: https://www.pharmafoods.co.jp/ Representative: Please refer to the website.
Inquiries: Please refer to the website.
Telephone: +81-75-394-8600
Scheduled date to commence dividend payments: -
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None
(Yen amounts are rounded down to millions, unless otherwise noted.)
-
Consolidated financial results for the nine months ended April 30, 2025 (from August 1, 2024 to April 30, 2025)
-
Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)
Net sales
Operating profit
Ordinary profit
Profit attributable to owners of parent
Nine months ended
Millions of yen
%
Millions of yen
%
Millions of yen
%
Millions of yen
%
April 30, 2025
46,817
(0.8)
(217)
-
(231)
-
(1,123)
-
April 30, 2024
47,171
(10.2)
3,266
99.9
3,223
103.7
1,856
73.7
Note: Comprehensive income For the nine months ended April 30, 2025:
¥(1,486) million
[-%]
For the nine months ended April 30, 2024:
¥1,877 million
[47.2%]
Basic earnings per share
Diluted earnings per share
Nine months ended
Yen
Yen
April 30, 2025
(39.18)
-
April 30, 2024
65.00
-
- Consolidated financial position
Total assets
Net assets
Equity-to-asset ratio
As of
Millions of yen
Millions of yen
%
April 30, 2025
32,585
10,239
31.4
July 31, 2024
36,573
11,585
31.7
Reference: Equity
As of April 30, 2025: ¥10,239 million
As of July 31, 2024: ¥11,585 million
-
Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)
-
Cash dividends
Annual dividends per share
First quarter-end
Second quarter-end
Third quarter-end
Fiscal year-end
Total
Yen
Yen
Yen
Yen
Yen
Fiscal year ended July 31, 2024
-
10.00
-
15.00
25.00
Fiscal year ending July 31, 2025
-
12.50
-
Fiscal year ending July 31, 2025
(Forecast)
12.50
25.00
Note: Revisions to the forecast of cash dividends most recently announced: None
- Forecast of consolidated financial results for the fiscal year ending July 31, 2025 (from August 1, 2024 to July 31, 2025)
(Percentages indicate year-on-year changes.)
Net sales | Operating profit | Ordinary profit | Profit attributable to owners of parent | Basic earnings per share | |||||
Fiscal year ending July 31, 2025 | Millions of yen 65,000 | % 4.6 | Millions of yen 2,000 | % (60.9) | Millions of yen 2,300 | % (56.2) | Millions of yen 1,600 | % (50.1) | Yen 57.00 |
Note: Revisions to the earnings forecasts most recently announced: None
* NotesSignificant changes in the scope of consolidation during the period: None
Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None
Changes in accounting policies, changes in accounting estimates, and restatement
Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
Changes in accounting policies due to other reasons: None
Changes in accounting estimates: None
Restatement: None
Number of issued shares (common shares)
Total number of issued shares at the end of the period (including treasury shares)
As of April 30, 2025
29,079,000 shares
As of July 31, 2024
29,079,000 shares
Number of treasury shares at the end of the period
As of April 30, 2025
22,378 shares
As of July 31, 2024
1,006,767 shares
Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)
Nine months ended April 30, 2025 | 28,690,110 shares |
Nine months ended April 30, 2024 | 28,564,866 shares |
Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm:Yes (optional)
Proper use of earnings forecasts, and other special matters
(Cautions on forward-looking statements, etc.)
The forward-looking statements, including forecasts of financial results, contained in these materials are based on information available to the Company and on certain assumptions deemed to be reasonable. Actual financial results may differ from the results anticipated in the statements due to various factors. For the assumptions and other matters related to the above forecasts, please refer to "1. Summary of Operating Results, etc. (3) Explanation of Forward-Looking Information such as Consolidated Earnings Forecasts."
(Method of accessing supplementary material on financial results)
Supplementary financial results materials will be posted on the Company's website on June 10, 2025.
Quarterly consolidated balance sheet | |||
(Millions of yen) | |||
As of July 31, 2024 | As of April 30, 2025 | ||
Assets | |||
Current assets | |||
Cash and deposits | 15,666 | 10,348 | |
Notes and accounts receivable - trade | 4,038 | 4,402 | |
Electronically recorded monetary claims - operating | 258 | 217 | |
Merchandise and finished goods | 5,292 | 5,368 | |
Work in process | 619 | 838 | |
Raw materials and supplies | 806 | 606 | |
Other | 596 | 1,444 | |
Allowance for doubtful accounts | (2) | (0) | |
Total current assets | 27,275 | 23,225 | |
Non-current assets
Property, plant and equipment
Buildings and structures, net | 2,157 | 2,110 |
Machinery, equipment and vehicles, net | 725 | 632 |
Tools, furniture and fixtures, net | 509 | 572 |
Land | 1,190 | 1,194 |
Leased assets, net | 11 | 30 |
Construction in progress | 16 | 162 |
Total property, plant and equipment | 4,609 | 4,703 |
Intangible assets | ||
Goodwill | 124 | 81 |
Other | 52 | 53 |
Total intangible assets | 177 | 135 |
Investments and other assets | ||
Investment securities | 3,037 | 2,586 |
Deferred tax assets | 351 | 880 |
Other | 1,122 | 1,055 |
Total investments and other assets | 4,510 | 4,522 |
Total non-current assets | 9,298 | 9,360 |
Total assets | 36,573 | 32,585 |
(Millions of yen)
As of July 31, 2024 | As of April 30, 2025 | |||
Liabilities | ||||
Current liabilities | ||||
Notes and accounts payable - trade | 1,250 | 1,296 | ||
Short-term borrowings | 14,900 | 11,900 | ||
Current portion of long-term borrowings | 760 | 560 | ||
Accounts payable - other | 4,039 | 5,492 | ||
Income taxes payable | 1,384 | 745 | ||
Provision for bonuses | 72 | 166 | ||
Other | 755 | 965 | ||
Total current liabilities | 23,163 | 21,125 | ||
Non-current liabilities | ||||
Long-term borrowings | 1,231 | 811 | ||
Retirement benefit liability | 384 | 360 | ||
Other | 208 | 47 | ||
Total non-current liabilities | 1,824 | 1,219 | ||
Total liabilities | 24,987 | 22,345 | ||
Net assets | ||||
Shareholders' equity | ||||
Share capital | 2,043 | 2,043 | ||
Capital surplus | 1,814 | 1,814 | ||
Retained earnings | 8,356 | 6,198 | ||
Treasury shares | (1,194) | (20) | ||
Total shareholders' equity | 11,019 | 10,036 | ||
Accumulated other comprehensive income | ||||
Valuation difference on available-for-sale securities | 566 | 203 | ||
Total accumulated other comprehensive income | 566 | 203 | ||
Total net assets | 11,585 | 10,239 | ||
Total liabilities and net assets | 36,573 | 32,585 |
Quarterly consolidated statement of income | |||
(Millions of yen) | |||
Nine months ended April 30, 2024 | Nine months ended April 30, 2025 | ||
Net sales | 47,171 | 46,817 | |
Cost of sales | 9,869 | 9,090 | |
Gross profit | 37,301 | 37,726 | |
Selling, general and administrative expenses | |||
Research and development expenses | 705 | 960 | |
Advertising expenses | 24,397 | 28,318 | |
Commission expenses | 3,171 | 3,187 | |
Amortization of goodwill | 81 | 43 | |
Other | 5,679 | 5,433 | |
Total selling, general and administrative expenses | 34,035 | 37,944 | |
Operating profit (loss) | 3,266 | (217) | |
Non-operating income | |||
Interest income | 1 | 6 | |
Dividend income | 14 | 15 | |
Foreign exchange gains | 8 | - | |
Subsidy income | 33 | 140 | |
Gain on investments in investment partnerships | - | 2 | |
Outsourcing service income | 12 | 12 | |
Other | 27 | 43 | |
Total non-operating income | 98 | 222 | |
Non-operating expenses | |||
Interest expenses | 44 | 68 | |
Foreign exchange losses | - | 11 | |
Loss on investments in investment partnerships | 2 | - | |
Share of loss of entities accounted for using equity method | 28 | 120 | |
Commission expenses | 26 | 17 | |
Other | 38 | 19 | |
Total non-operating expenses | 140 | 236 | |
Ordinary profit (loss) | 3,223 | (231) | |
Extraordinary income | |||
Gain on sale of investment securities | 10 | - | |
Total extraordinary income | 10 | - | |
Profit (loss) before income taxes | 3,234 | (231) | |
Income taxes | 1,377 | 892 | |
Profit (loss) | 1,856 | (1,123) | |
Profit (loss) attributable to owners of parent | 1,856 | (1,123) | |